Nuveen LLC Invests $300,000 in Fate Therapeutics, Inc. $FATE

Nuveen LLC bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 379,088 shares of the biopharmaceutical company’s stock, valued at approximately $300,000. Nuveen LLC owned about 0.33% of Fate Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Squarepoint Ops LLC raised its stake in Fate Therapeutics by 154.2% in the 4th quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 20,805 shares in the last quarter. Hsbc Holdings PLC raised its stake in Fate Therapeutics by 22.0% in the 4th quarter. Hsbc Holdings PLC now owns 109,422 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 19,706 shares in the last quarter. Millennium Management LLC raised its stake in Fate Therapeutics by 28.9% in the 4th quarter. Millennium Management LLC now owns 413,192 shares of the biopharmaceutical company’s stock worth $682,000 after purchasing an additional 92,576 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Fate Therapeutics by 10.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,898,377 shares of the biopharmaceutical company’s stock worth $4,782,000 after purchasing an additional 279,360 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Fate Therapeutics by 65.2% in the 4th quarter. BNP Paribas Financial Markets now owns 287,711 shares of the biopharmaceutical company’s stock worth $475,000 after purchasing an additional 113,563 shares in the last quarter. Institutional investors and hedge funds own 97.54% of the company’s stock.

Fate Therapeutics Trading Up 3.8%

Shares of Fate Therapeutics stock opened at $1.01 on Friday. The firm has a market capitalization of $116.48 million, a PE ratio of -0.70 and a beta of 2.21. The firm’s 50 day moving average is $1.11 and its 200 day moving average is $1.12. Fate Therapeutics, Inc. has a 1 year low of $0.66 and a 1 year high of $4.20.

Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%. The firm had revenue of $1.91 million for the quarter, compared to analyst estimates of $1.16 million. As a group, research analysts anticipate that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on FATE. Wall Street Zen upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 18th. Barclays dropped their price objective on shares of Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. Robert W. Baird dropped their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, May 14th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a research report on Thursday, June 12th. Finally, Wells Fargo & Company dropped their target price on shares of Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating for the company in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Fate Therapeutics presently has an average rating of “Hold” and a consensus price target of $3.30.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.